Results 31 to 40 of about 16,268 (199)
Microbiology Spectrum, 2023 Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj +1 more source
Effect of β-lactamase inhibitors on in vitro activity of β-lactam antibiotics against Burkholderia cepacia complex species [PDF]
, 2016 Background: Bacteria belonging to the Burkholderia cepacia complex (Bcc) are an important cause of chronic respiratory tract infections in cystic fibrosis patients. Intrinsic resistance to a wide range of antimicrobial agents, including a variety of beta-
Coenye, Tom, Everaert, Annelien
core +2 more sources
Frontiers in Pharmacology, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li +8 more
doaj +1 more source
Multi-drug resistant Gram-negative bacteria: antibiotic-resistance and new treatment strategies [PDF]
, 2017 In this editorial, we treat the multi-drug-resistance of microorganisms such as Klebsiella pneumonia (Kp) and Acinetobacter baumanii and the issues concerning the management of these infections.
Angelis, Massimiliano De +2 more
core +1 more source
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
Antibiotics, 2021 The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci +3 more
doaj +1 more source
The Surgical Infection Society revised guidelines on the management of intra-abdominal infection [PDF]
, 2017 Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update
Chang, Phillip K +11 more
core +3 more sources
Antibiotics, 2021 Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Carola Mauri +4 more
doaj +1 more source
AmpC β-lactamase induction by avibactam and relebactam [PDF]
, 2017 Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota +5 more
core +1 more source
Antibiotics, 2023 Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-β-lactamase (MBL)-positive strains, has led to limited treatment options ...
Denis Piérard +3 more
doaj +1 more source
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia [PDF]
, 2017 Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus ...
Chen, Q. +9 more
core +1 more source